Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law…. By: Latham & Watkins LLP
Previous Story
Product Liability and Mass Tort Monitor: August 2026 Edition
Next Story
AI in organizations: It is no longer enough to say “Do not input confidential information”
